2020
351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009
Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Journal For ImmunoTherapy Of Cancer 2020, 8: a376-a376. DOI: 10.1136/jitc-2020-sitc2020.0351.Peer-Reviewed Original ResearchPlatinum-based chemotherapyRecurrent/metastatic headNeck squamous cell carcinomaECOG performance statusSquamous cell carcinomaDisease progressionLenvatinib monotherapyM HNSCCCell carcinomaRECIST v1.1SOC chemotherapyMetastatic headMonotherapy armPerformance statusTreatment optionsPhase Ib/II trialStandard first-line treatment optionPD-L1 tumor proportion scoreFirst-line treatment optionAdvanced renal cell carcinomaJ Clin OncolSafety of pembrolizumabPD-1 inhibitorsPlatinum-containing chemotherapyAdvanced solid tumors
2018
1047PD Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial
Le Tourneau C, Cohen E, Harrington K, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby R, Soulières D. 1047PD Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. Annals Of Oncology 2018, 29: viii373-viii374. DOI: 10.1093/annonc/mdy287.003.Peer-Reviewed Original Research
2012
Informational needs of head and neck cancer patients
Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA. Informational needs of head and neck cancer patients. Health And Technology 2012, 2: 57-62. PMID: 22518350, PMCID: PMC3327509, DOI: 10.1007/s12553-012-0020-9.Peer-Reviewed Original ResearchHNSCC patientsNeck squamous cell carcinomaEarly-stage diseaseMajority of patientsSquamous cell carcinomaConsiderable functional impairmentNeck cancer patientsInformational needsPatients' informational needsQuality of lifeInternet-based programAdvanced diseaseMost patientsYounger patientsMale patientsFemale patientsMajority of participantsCell carcinomaPatient populationCancer patientsTreatment optionsFunctional impairmentPatientsPsychosocial needsEmotional stress